Trial Profile

A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Retlirafusp alfa (Primary)
Indications Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Suzhou Suncadia Biopharmaceuticals

Most Recent Events

24 Oct 2023 Results (As of Mar 31, 2023,n=67) assessing safety and efficacy of SHR-1701 plus bevacizumab in patients with advanced solid tumors, presented at the 48th European Society for Medical Oncology Congress.
09 Aug 2021 Status changed from not yet recruiting to recruiting.
29 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com